- Company
-
- Aifinyo AG
- Aixtron SE
- Berentzen Gruppe AG
- Brain Biotech AG
- Carl Zeiss Meditec AG
- Deutz AG
- Edag Engineering Group AG
- ElringKlinger AG
- Encavis AG
- Energiekontor AG
- Hypoport SE
- Jost Werke SE
- Knaus Tabbert AG
- LEG Immobilien SE
- Media and Games Invest SE
- Mister Spex SE
- Mountain Alliance AG
- Mutares SE
- Nemetschek SE
- Rational AG
- Schaltbau Holding AG
- SFC Energy AG
- Sixt SE
- Talanx AG
- USU Software AG
- Varta AG
- voxeljet AG
- Wacker Chemie AG
- Zeal Network SE
- Presentations
- Sector
- Index
- Speaker
- About
- Blog
January 16, 2023
15:49 
BRAIN Biotech AG FY 2021/22: Key Takeaways
Revenue Growth in BRAIN Biotech AG
BRAIN Biotech AG, a leading provider of biologization solutions for industries, has reported strong revenue growth in both segments, contributing to a total group revenue increase of 35% and an organic increase of 19% in the first quarter the fiscal year 2022/23.
Â
BioIndustrial and BioScience Segment Performance
The BioIndustrial segment saw revenue growth of 43.5%, and the BioScience segment’s revenue increased by 10.5% on an organic basis. The company’s cash on hand also improved by €2.4 million to €10.8 million, including the proceeds from the disposal of L.A. Schmitt GmbH.
Â
Profitability and Investments
Despite higher personnel and project investments, BRAIN Biotech’s adjusted EBITDA remained profitable.
Â
Quarterly Highlights and Collaborations
Important events for the quarter included MP Beteiligungs-GmbH expanding its shareholding to approximately 45% and the company reaching project milestones in its collaboration with rare sugars expert Bonumose.
Â
CFO Insights into Fiscal Year Prospects
Michael Schneiders, CFO, expressed optimism for the rest of the fiscal year, noting the company’s solid growth as a foundation for handling inflationary costs.
Chapters
- Brain at a Glance
- Group Structure
- Highlights FY21/22
- Lowlights FY21/22
- Akibion Genomics
- Brain Incubator
- Financial Highlights FY21/22
- Cash & Cash Flow
- Long-Term Revenue Growth Trajectory
- Adjusted Ebitda
- Revenue by Region
- General Risk Factors
- Targets
- Share Ownership
- Financial Calendar
Resources
Host
Share
T&C:
This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/
Continuing the Journey: More Presentations
Discover Additional Elevator Pitches
Reviews for BRAIN Biotech AG Financial Results FY 2021 / 22 | Exploring Growth, Challenges, and Future Prospects with CFO
There are currently no reviews for BRAIN Biotech AG Financial Results FY 2021 / 22 | Exploring Growth, Challenges, and Future Prospects with CFO